{"name": "BioVex",
 "permalink": "biovex",
 "crunchbase_url": "http://www.crunchbase.com/company/biovex",
 "homepage_url": "http://www.biovex.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": null,
 "category_code": "biotech",
 "number_of_employees": 29,
 "founded_year": 2006,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "enquiries@biovex.com",
 "phone_number": "+44 (0)1235 441900 ",
 "description": "Biological Treatment For Cancer ",
 "created_at": "Fri Mar 13 13:55:05 UTC 2009",
 "updated_at": "Mon Aug 01 17:42:50 UTC 2011",
 "overview": "\u003Cp\u003EBioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. \u003C/p\u003E\n\n\u003Cp\u003ETheir cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in \u0026gt;110 patients in a broad range of solid tumors including melanoma, head \u0026amp; neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       40],
      "assets/images/resized/0004/9487/49487v2-max-150x150.jpg"],
     [[250,
       68],
      "assets/images/resized/0004/9487/49487v2-max-250x250.jpg"],
     [[294,
       80],
      "assets/images/resized/0004/9487/49487v2-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chief Technology Officer, Founder and Director",
    "person":
     {"first_name": "Dr",
      "last_name": "Robert Coffin",
      "permalink": "dr-robert-coffin",
      "image": null}},
   {"is_past": false,
    "title": "MD, Chief Medical Officer",
    "person":
     {"first_name": "Howard",
      "last_name": "Goldsweig",
      "permalink": "howard-goldsweig",
      "image": null}},
   {"is_past": false,
    "title": "President, Chief Executive Officer and Director",
    "person":
     {"first_name": "Philip",
      "last_name": "Astley-Sparke",
      "permalink": "philip-astley-sparke",
      "image": null}},
   {"is_past": false,
    "title": "SVP Product Development",
    "person":
     {"first_name": "Dr",
      "last_name": "Colin Love",
      "permalink": "dr-colin-love",
      "image": null}},
   {"is_past": false,
    "title": "Chief Financial Officer , Treasurer and Secretary",
    "person":
     {"first_name": "Stephen",
      "last_name": "Gorgol",
      "permalink": "stephen-gorgol",
      "image": null}},
   {"is_past": false,
    "title": "VP Operations",
    "person":
     {"first_name": "Lance",
      "last_name": "Weed",
      "permalink": "lance-weed",
      "image": null}},
   {"is_past": true,
    "title": "Board Observer",
    "person":
     {"first_name": "Joel",
      "last_name": "Jean Mairet",
      "permalink": "joel-jean-mairet",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0026/9034/269034v1-max-150x150.jpg"],
          [[182,
            250],
           "assets/images/resized/0026/9034/269034v1-max-250x250.jpg"],
          [[194,
            266],
           "assets/images/resized/0026/9034/269034v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "\u00a387M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.redorbit.com/news/health/993936/biovex_raises_22_million_in_first_close_of_series_e/index.html",
    "source_description": "BioVex Raises $22 Million in First Close of Series E Financing",
    "raised_amount": 17000000.0,
    "raised_currency_code": "GBP",
    "funded_year": 2007,
    "funded_month": 11,
    "funded_day": 15,
    "investments":
     []},
   {"round_code": "f",
    "source_url": "http://www.fiercebiotech.com/story/biovex-raises-40m-series-f/2009-03-30",
    "source_description": "BioVex Raises $40 Million",
    "raised_amount": 40000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 3,
    "funded_day": 30,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Forbion Capital Partners",
         "permalink": "forbion-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0010/0907/100907v1-max-150x150.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-250x250.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Credit Agricole Private Equity",
         "permalink": "credit-agricole-private-equity",
         "image":
          {"available_sizes":
            [[[150,
               41],
              "assets/images/resized/0002/3491/23491v3-max-150x150.jpg"],
             [[250,
               68],
              "assets/images/resized/0002/3491/23491v3-max-250x250.jpg"],
             [[450,
               123],
              "assets/images/resized/0002/3491/23491v3-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Harris \u0026 Harris Group",
         "permalink": "harris-harris-group",
         "image":
          {"available_sizes":
            [[[150,
               30],
              "assets/images/resized/0003/2214/32214v2-max-150x150.jpg"],
             [[250,
               51],
              "assets/images/resized/0003/2214/32214v2-max-250x250.jpg"],
             [[313,
               64],
              "assets/images/resized/0003/2214/32214v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Innoven Partners",
         "permalink": "innoven-partenaires",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0002/9306/29306v2-max-150x150.png"],
             [[221,
               116],
              "assets/images/resized/0002/9306/29306v2-max-250x250.png"],
             [[221,
               116],
              "assets/images/resized/0002/9306/29306v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Science Ventures",
         "permalink": "new-science-ventures",
         "image":
          {"available_sizes":
            [[[150,
               88],
              "assets/images/resized/0004/2733/42733v2-max-150x150.png"],
             [[158,
               93],
              "assets/images/resized/0004/2733/42733v2-max-250x250.png"],
             [[158,
               93],
              "assets/images/resized/0004/2733/42733v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Triathlon Medical Venture Partners",
         "permalink": "triathlon-medical-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0004/5663/45663v2-max-150x150.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-250x250.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Scottish Equity Partners",
         "permalink": "scottish-equity-partners",
         "image":
          {"available_sizes":
            [[[150,
               130],
              "assets/images/resized/0002/9935/29935v9-max-150x150.jpg"],
             [[250,
               217],
              "assets/images/resized/0002/9935/29935v9-max-250x250.jpg"],
             [[450,
               391],
              "assets/images/resized/0002/9935/29935v9-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "f",
    "source_url": "http://www.xconomy.com/boston/2009/11/10/biovex-nails-down-another-30m-to-finish-pivotal-study-of-cancer-killing-virus/",
    "source_description": "Xconomy Boston",
    "raised_amount": 30000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 11,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Morningside Venture Investments",
         "permalink": "morningside-venture-investments",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Ventech",
         "permalink": "ventech-capital",
         "image":
          {"available_sizes":
            [[[150,
               150],
              "assets/images/resized/0002/9792/29792v4-max-150x150.jpg"],
             [[250,
               250],
              "assets/images/resized/0002/9792/29792v4-max-250x250.jpg"],
             [[450,
               450],
              "assets/images/resized/0002/9792/29792v4-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MVM Life Science Partners",
         "permalink": "mvm-life-science-partners",
         "image":
          {"available_sizes":
            [[[112,
               59],
              "assets/images/resized/0006/8440/68440v2-max-150x150.png"],
             [[112,
               59],
              "assets/images/resized/0006/8440/68440v2-max-250x250.png"],
             [[112,
               59],
              "assets/images/resized/0006/8440/68440v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sectoral Asset Management",
         "permalink": "sectoral-asset-management",
         "image":
          {"available_sizes":
            [[[150,
               42],
              "assets/images/resized/0006/3989/63989v1-max-150x150.jpg"],
             [[228,
               65],
              "assets/images/resized/0006/3989/63989v1-max-250x250.jpg"],
             [[228,
               65],
              "assets/images/resized/0006/3989/63989v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Ysios Capital",
         "permalink": "ysios-capital",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0006/3990/63990v2-max-150x150.png"],
             [[160,
               21],
              "assets/images/resized/0006/3990/63990v2-max-250x250.png"],
             [[160,
               21],
              "assets/images/resized/0006/3990/63990v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition":
  {"price_amount": 1000000000.0,
   "price_currency_code": "USD",
   "term_code": "cash",
   "source_url": "http://www.masshightech.com/stories/2011/01/24/daily17-BioVex-to-be-acquired-by-Amgen-for-up-to-1-billion.html",
   "source_description": "BioVex to be acquired by Amgen for up to $1 billion",
   "acquired_year": 2011,
   "acquired_month": 1,
   "acquired_day": 25,
   "acquiring_company":
    {"name": "Amgen",
     "permalink": "amgen",
     "image":
      {"available_sizes":
        [[[97,
           28],
          "assets/images/resized/0005/9904/59904v1-max-150x150.jpg"],
         [[97,
           28],
          "assets/images/resized/0005/9904/59904v1-max-250x250.jpg"],
         [[97,
           28],
          "assets/images/resized/0005/9904/59904v1-max-450x450.jpg"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "BioVex Ltd",
    "address1": "70 Milton Park",
    "address2": "Abingdon",
    "zip_code": "OX14 4RX ",
    "city": "Oxon",
    "state_code": null,
    "country_code": "GBR",
    "latitude": 51.671711,
    "longitude": -1.289082},
   {"description": "BioVex Inc ",
    "address1": "34 Commerce Way ",
    "address2": "",
    "zip_code": "MA 01801",
    "city": "Woburn",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": 42.508964,
    "longitude": -71.13287}],
 "milestones":
  [{"description": "has launched a Phase 3 study of its OncoVEXGM-CSF as a treatment for patients with locally advanced squamous cell carcinoma of the head and neck.",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 10,
    "source_url": "http://www.masshightech.com/stories/2010/12/06/daily58-BioVex-launches-Phase-3-study-on-head-and-neck-cancer-treatment.html",
    "source_text": null,
    "source_description": "BioVex launches Phase 3 study on head and neck cancer treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "BioVex",
      "permalink": "biovex"}},
   {"description": "Amgen, has reached agreement to acquire BioVex Group Inc. for what could total $1 billion",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 25,
    "source_url": "http://www.masshightech.com/stories/2011/01/24/daily17-BioVex-to-be-acquired-by-Amgen-for-up-to-1-billion.html",
    "source_text": null,
    "source_description": "BioVex to be acquired by Amgen for up to $1 billion",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "BioVex",
      "permalink": "biovex"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        86],
       "assets/images/resized/0007/5384/75384v1-max-150x150.jpg"],
      [[250,
        144],
       "assets/images/resized/0007/5384/75384v1-max-250x250.jpg"],
      [[450,
        260],
       "assets/images/resized/0007/5384/75384v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  [{"external_url": "http://bit.ly/biovex",
    "title": "BioVex melanoma results in comparison to the competition"}]}